Phase 2 Study of TLK286 in Metastatic Breast Cancer

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Arizona Cancer Center, Tucson, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologic diagnosis of breast cancer
Metastatic disease
Measurable or evaluable disease
No prior chemotherapy regimens
Age at least 18 years
Adequate liver and kidney function
Adequate bone marrow function

Exclusion criteria

Pregnant or lactating women
Unstable medical conditions
Chemotherapy within 14 days of TLK286
Radiation therapy within 14 days of TLK286
Hormonal therapy within 14 days of TLK286
Immunotherapy within 14 days of TLK286
CNS metastasis unless controlled by treatment

Treatment and study plan

TLK286

Drug

Sponsors and collaborators

Lead sponsor

Telik

Industry

Registry information

Important dates

Study start: 2002
Primary completion: 2004
Study completion: 2004
First posted: May 7, 2002
Registry last updated: Jul 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed